Imaging for Suspected Fatty Liver Disease
Start with abdominal ultrasound as the initial imaging study for evaluating suspected fatty liver disease, as it is widely available, cost-effective, and has good diagnostic performance for detecting moderate-to-severe steatosis 1, 2.
Initial Imaging Approach
Ultrasound (US) is the first-line imaging modality for patients with suspected fatty liver disease 2, 3. It provides reasonable accuracy for detecting moderate-to-severe hepatic steatosis and is the most practical option in routine clinical practice 4, 3. The examination identifies fatty liver through increased liver echogenicity and attenuation of ultrasound waves in deeper liver tissue 4.
Key Limitations of Ultrasound to Consider:
- Reduced sensitivity for mild steatosis (may miss early disease)
- Limited accuracy in obese patients due to body habitus
- Operator-dependent with subjective interpretation
- Cannot reliably quantify exact fat content 3
Advanced Imaging When Ultrasound is Inadequate
If ultrasound is limited by obesity, NAFLD itself, or nodular cirrhotic liver, proceed to MRI or CT 2.
MRI-Based Techniques (Preferred for Quantification):
- MR spectroscopy or MRI-derived proton density fat fraction (PDFF) are the most accurate noninvasive methods for quantifying hepatic fat content 1, 3, 5
- These techniques provide highly accurate and reproducible measurements and serve as the reference standard in clinical trials 3
- MRI without contrast with diffusion-weighted imaging (DWI) can detect steatosis when IV contrast is contraindicated 2
CT Limitations:
- Generally unsuitable as a primary modality due to radiation exposure and limited accuracy for mild steatosis 3
- May be appropriate (rating 7/9) for specific surveillance scenarios but not for initial fatty liver evaluation 2
Assessing Fibrosis Risk (Critical for Prognosis)
Beyond detecting steatosis, you must assess for advanced fibrosis, as this determines outcomes 1. The natural history is dichotomous—simple steatosis is generally benign, while steatohepatitis with fibrosis can progress to cirrhosis and liver cancer 1.
Noninvasive Fibrosis Assessment:
- Vibration-controlled transient elastography (VCTE/FibroScan) with controlled attenuation parameter (CAP) can simultaneously assess both steatosis and fibrosis 1, 4
- Clinical decision aids like NFS (NAFLD Fibrosis Score) or FIB-4 index identify patients at low or high risk for advanced fibrosis 1
- MR elastography can diagnose fibrosis and cirrhosis when performed with MRI for steatosis screening 2
Clinical Context Matters
Patients with type 2 diabetes warrant particularly high suspicion and thorough evaluation 1. Those with multiple metabolic risk factors (diabetes, hypertension, dyslipidemia, visceral obesity) are at highest risk for progressive liver disease and adverse outcomes 1.
Important Caveats:
- Routine screening of asymptomatic patients is NOT currently recommended due to uncertainties about treatment options and cost-effectiveness 1
- Screening family members is not recommended 1
- However, maintain high clinical suspicion in high-risk groups (diabetes, obesity clinics)
Practical Algorithm
- Initial evaluation: Abdominal ultrasound
- If US limited or inadequate: MRI with PDFF or MR spectroscopy
- Simultaneously assess fibrosis risk: VCTE/FibroScan with CAP, or calculate FIB-4/NFS
- If high fibrosis risk or diabetes present: Consider MR elastography or more intensive monitoring
The goal is not just detecting fat, but stratifying fibrosis risk, as fibrosis stage—not steatosis grade—determines liver-related mortality 1.